StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a report published on Thursday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Tenax Therapeutics Trading Up 1.2 %
NASDAQ TENX opened at $3.49 on Thursday. The business’s 50-day moving average price is $3.73 and its two-hundred day moving average price is $3.61. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $61.20.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16. As a group, sell-side analysts anticipate that Tenax Therapeutics will post -6.68 earnings per share for the current year.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Featured Stories
- Five stocks we like better than Tenax Therapeutics
- What is the FTSE 100 index?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- MarketBeat Week in Review – 9/23 – 9/27
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.